Once-daily maraviroc plus boosted atazanavir promising at 96 weeks
Adolescent antiretroviral options expanding
New antiretrovirals for infants and children still needed
Four-class, five-drug regimen given to monkeys shows signs of producing long-term viral load reductions off treatment
The road to PrEP: trials, regulation and roll-out
Study shows that use of darunavir/ritonavir and etravirine in HIV treatment as a prevention method is biologically plausible
Elvitegravir Quad pill matches efavirenz and atazanavir combos
Novel integrase inhibitor dolutegravir still potent at 96 weeks
Tenofovir pro-drug GS-7340 shows good safety and efficacy in short study
